

File downloaded on 2026-04-24

Source URL: <https://medicines.health.europa.eu/veterinary/en/600000061934>

Rispoval IBR-Marker InactivatumSuspension for injection for cattle

Authorised

- Bovine herpesvirus 1, strain Difivac gE gene-deleted, Inactivated

Product identification

Medicine name:

Rispoval IBR-Marker InactivatumSuspension for injection for cattle

Active substance:

Bovine herpesvirus 1, strain Difivac gE gene-deleted, Inactivated

Target species:

Cattle

Cattle (for meat production)

Cattle (calf)

Cattle (heifer)

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Bovine herpesvirus 1, strain Difivac gE gene-deleted, Inactivated
0.01 titre / 2.00 millilitre(s)

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

-

Cattle

- Milk. 0 day
- Meat and offal. 0 day

-

Cattle (for meat production)

- Meat and offal. 0 day

-

Cattle (calf)

- Meat and offal. 0 day

-

Cattle (heifer)

- Meat and offal. 0 day
-

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI02AA03

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Slovakia

Package description:

(ID3) 100 millilitre(s): Box (Cardboard) with 1 Bottle (Glass) with 100 millilitre(s)

(ID2) 20 millilitre(s): Box (Cardboard) with 1 Bottle (Glass) with 20 millilitre(s)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Ceska Republika s.r.o.

Marketing authorisation date:

1/10/2008

Manufacturing sites for batch release:

Zoetis Belgium

Responsible authority:

Institute For State Control Of Veterinary Biologicals And Medicaments

Authorisation number:

97/035/MR/08-S

Date of authorisation status change:

1/10/2008

Reference member state:

Germany

Procedure number:

DE/V/0021/001

Concerned member states:

Belgium Bulgaria Czechia Estonia France Hungary Ireland Italy Latvia
Lithuania Luxembourg Netherlands Poland Portugal Romania Slovakia
Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents

English (PDF)

Published on: 28/06/2024

[Download](#)